GlassScriptPhysician profile
Blessy B Maris
NPI 1245808294
$674.35
in general payments reported to CMS, 2019-2025
13 companies · $102 in 2025
The $102 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $27.55 · 2023: $310 · 2024: $235 · 2025: $102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $647.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $646.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $133.96 | 2023 | Proclaim |
| Collegium Pharmaceutical, INC. | $128.27 | 2022-2025 | Belbuca, Xtampza |
| Vertos Medical, INC. | $113.20 | 2024 | Mild Device Kit |
| Azurity Pharmaceuticals, INC. | $64.76 | 2023-2025 | Horizant, Horizant |
| Ibsa Pharma INC. | $45.63 | 2023-2024 | Tirosint, Licart, Licart |
| Spr Therapeutics, INC | $36.40 | 2025 | Sprint Pns System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.05 | 2024 | Relistor |
| Glaxosmithkline, LLC. | $28.27 | 2023 | Trelegy Ellipta, Shingrix |
| Electronic Waveform Lab, INC. | $24.61 | 2023 | |
| Averitas Pharma INC. | $18.46 | 2025 | Qutenza |
| Novo Nordisk INC | $18.26 | 2023 | Wegovy |
| Abbvie INC. | $16.31 | 2024 | |
| Amgen INC. | $15.17 | 2024 | Evenity, Prolia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blessy Maris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.